HOCK LOCK SIEW
·
SUBSCRIBERS

The privatisation offer for this small Catalist company could cause SGX some discomfort

The proposal to take Singapore Paincare private comes a mere five years after IPO, and highlights the local bourse’s chronic lack of liquidity

Megan Cheah
Published Tue, Jun 3, 2025 · 06:42 PM
    • Singapore Paincare CEO Dr Bernard Lee (above) and COO Dr Jeffrey Loo are looking to take the company private at S$0.16 per share.
    • Singapore Paincare CEO Dr Bernard Lee (above) and COO Dr Jeffrey Loo are looking to take the company private at S$0.16 per share. PHOTO: BT FILE

    [SINGAPORE] Amid a flurry of delistings from the Singapore Exchange (SGX), one more privatisation offer – especially that for a small Catalist player – should not make much of a difference.

    After all, the local bourse looks on pace to hit at least 20 delistings or privatisation offers in the first half of this year.

    Already, firms such as offshore oil-and-gas contractor Dyna-Mac and software company Silverlake Axis have delisted this year.

    Copyright SPH Media. All rights reserved.